California is currently home to 5617 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Recruiting
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from treatment with capecitabine. Participants will be monitored for changes in ctDNA in the blood over time received during capecitabine treatment. Results of ctDNA analysis will be correlated to genetic characteristics of individual tumors. This may inform future clinical tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Stanford University, Stanford, California
Conditions: Triple Negative Breast Cancer, Breast Cancer
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
Recruiting
Develop a NIRSIT testing protocol that can be administered in the diagnostic setting and reliably distinguishes the symptoms and severity of depression, with the help of repeated measure (up to five visits per subject) comparison of patients being treated for Major Depressive Disorder with control, non-depressed subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: San Francisco Veterans Affairs Medical Center, San Francisco, California
Conditions: Major Depressive Disorder
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
Recruiting
Patients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory, and other cognitive functions. These cognitive deficits frequently have significant impact on patient quality of life. Although currently, there is no established standard of care to treat cognitive deficits in brain tumor patients, standard cognitive rehabilitative trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Low-grade Glioma
Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Recruiting
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its growth and maintenance, but the side effects of currently approved angiogenesis inhibitors make these agents inappropriate for use in reproductive-age patients. This obstacle will be overcome by performing a randomized, double blind clinical trial aimed at repurposing an existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and young women with endometriosis. This trial pro... Read More
Gender:
FEMALE
Ages:
Between 15 years and 40 years
Trial Updated:
03/19/2025
Locations: Standford University, Palo Alto, California
Conditions: Endometriosis
Biomarkers for Risk Stratification in Lung Cancer
Recruiting
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/19/2025
Locations: Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California
Conditions: Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
The ILet Experience Study
Recruiting
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
03/18/2025
Locations: Beta Bionics, Irvine, California
Conditions: Type 1 Diabetes
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Recruiting
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovar... Read More
Gender:
FEMALE
Ages:
39 years and below
Trial Updated:
03/18/2025
Locations: Kaiser Permanente-Oakland, Oakland, California
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
VTP-1000 in Adults with Celiac Disease
Recruiting
GLU001 is a first-in-human clinical trial to assess the safety and tolerability of VTP-1000 for adults with celiac disease. This trial will assess VTP-1000 at various dose levels compared to placebo in a single ascending dose (SAD) and multiple ascending dose (MAD) format. Participants will be followed for a short period of time to assess the impact of VTP-1000 on their immune system (Adverse events, reactions in the blood, and physical exam differences). Participants enrolled in the MAD portion... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/18/2025
Locations: Parexel EPCU LA, Los Angeles, California
Conditions: Celiac Disease
Continuous Glucose Monitoring System Feasibility in Youth With T2D
Recruiting
The primary scientific question of this proposal is to investigate whether youth with T2D will wear and interact with a continuous glucose monitor (CGM) system and whether this will influence behavior and management decisions. There will be 30 participants enrolled in the study. 20 in the treatment arm and 10 in the control. The length of study participation will be 6 months for each participant.
Gender:
ALL
Ages:
Between 8 years and 20 years
Trial Updated:
03/18/2025
Locations: University of California San Francisco (UCSF), San Francisco, California
Conditions: Type 2 Diabetes
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome
Recruiting
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Center for Dermatology Clinical Research, Fremont, California
Conditions: Gorlin Syndrome
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Recruiting
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: California Research Institute, Los Angeles, California
Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Recruiting
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Oncology Physicians Network Healthcare, Glendale, California
Conditions: Non-small Cell Lung Cancer